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SUMMARY
While advances in patient care and immunosuppressive pharmacotherapies have increased the 
lifespan of heart allograft recipients, there are still significant comorbidities post-transplantation 
and 5-year survival rates are still significant, at approximately 70%. The last decade has seen 
massive strides in genomics and other omics fields, including transcriptomics, with many of these 
advances now starting to impact heart transplant clinical care. This review summarizes a number 
of the key advances in genomics which are relevant for heart transplant outcomes, and we 
highlight the translational potential that such knowledge may bring to patient care within the next 
decade.
Keywords
genes; genomics; histocompatibility and immunogenetics; immunobiology; molecular diagnostic; 
proteomics
Introduction
Heart transplantation is often the only available treatment for patients with significant 
congenital cardiac disease and/or end-stage heart failure [1,2]. Advances in 
immunosuppressive therapies (IST), surgical techniques, and preoperative and postoperative 
patient management have yielded substantial gains in short- and long-term post-transplant 
outcomes over the last few decades [2]. Despite these advances, the 5-year heart allograft 
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survival rates are ~71%, because of an interplay of immune related as well as nonimmune 
comorbidities including hypertension, diabetes, dyslipidemia, a range of coronary diseases, 
infection, renal insufficiency, and malignancies [3]. Acute rejection (AR) is most likely to 
occur in the first three to twelve months post-transplant, with at least one rejection episode 
occurring in upwards of 50% of cardiac transplant recipients. AR remains a frequent and 
life-threatening complication increasing the risk of acute and downstream graft damage [1,4] 
and greatly impacts the progression of chronic allograft vasculopathy (CAV), which is the 
leading cause of diminished cardiac allograft survival [1]. Acute and chronic rejection 
pathogeneses are complex, affected by many established factors such as human leukocyte 
antigen (HLA) mismatches, immunosuppression regimens, compliance, and recipient age 
[5].
Patients who receive renal allograft from HLA-identical donors can undergo acute or chronic 
rejection, indicating a role for non-HLA factors in alloimmunity [6]. Large-scale 
retrospective analyses of 10-year national registry data show that ~18% of allograft failures 
are attributable to donor–recipient (D-R) HLA genetic factors, with 38% of the failures 
reported to be caused by immunological reactions against non-HLA factors (as observed in 
HLA-identical sibling grafts) [7]. There is a clear lack of knowledge of the genetic 
underpinnings of allograft rejection and other complications of transplantation, and 
understanding these processes may advance clinical management of individual heart 
transplant recipients and impact short- and long-term allograft survival. While assessment of 
HLA compatibility for heart transplant donor–recipient (D-R) selection is an important 
factor for graft survival outcomes, it is not always predicated in all transplant centers, 
because of limited pools of available organs and time constraints with recovery of thoracic 
organs from deceased donors, but it is becoming increasingly implemented and standardized 
across national programs [8].
The last decade has seen staggering progress in genomic and other omic technologies, and 
their application in the Mendelian and complex disease arena. Since the initial draft 
sequences of the first human genomes nearly 15 years ago, genetic single nucleotide 
polymorphism (SNP) maps have been generated across the major human populations using 
genome-wide genotyping panels of typically >500 000 to several million SNP markers. This 
has facilitated the advent of genome-wide association studies (GWAS) which have led to the 
elucidation of robust genetic associations for the vast majority of polygenic traits and 
diseases with heritable components [9]. Subsequent advances in sequencing chemistries and 
advanced engineering allowed the capture and sequencing of the known gene-coding 
regions, termed whole-exome sequencing (WES) as well as whole-genome sequencing 
(WGS). These processes have become more affordable in the last 2–3 years, and sequencing 
of thousands of large reference populations has facilitated characterization of common and 
rarer genetic variants [10], leading to the broad observation that two unrelated human 
genomes differ by ~3.5 million to 10 million polymorphisms, depending on their respective 
ancestral backgrounds. WGS of human populations also shows that an average genome 
contains ~100 genuine loss-of-function (LoF) variants (defined as variants ablating all of 
part of a gene product/function), with ~20 genes having LoFs in both copies [11]. Two copy 
LoFs may cause graft rejection through the LoF gene product in the donor being treated as 
an allogenic epitope [12–16]. Additional sources of neo-antigens include stop-loss mutations 
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where the conventional stop codon is disrupted resulting in novel amino acids being 
synthesized. Indeed, recent WES in >15 500 human protein-coding genes in >2 000 
individuals of diverse ancestry identified more than 500 000 variants < 1% frequency with 
an average of >13 500 low-frequency variants observed per individual, of which ~2% was 
predicted to impact the function of > 300 genes, per genome assessed [11,17]. While it is 
clear that a broad spectrum of genetic differences could represent significant reservoirs of 
potential mHA differences which could potentially contribute to allogenicity and thus acute 
rejection pathology, there have been limited efforts to date to look at the global mismatches 
of amino acids between donors and recipients.
Studies of genetic polymorphisms in association studies using large well-characterized heart 
transplant cohorts are currently lacking. We also discuss how advances in genome-wide 
tools can be used to unveil sources of potential alloimmunity in, and beyond, conventional 
HLA regions, and we outline a number of key genomic studies in pharmacological genes 
(pharmacogenes) relevant in the transplant setting and where such knowledge may begin to 
be implemented in broader clinical care in pre- and postcardiac transplant clinical 
management. We discuss a recently formed transplant genomic consortium whose aims are 
to discover and validate genome-wide associations for a number of complications post-
transplant. We also outline recent advances in the development of molecular characterization 
of allograft biopsies, as well as noninvasive or minimally invasive biofluids, for diagnoses 
and prognostication of acute rejection. This is particularly relevant in the post-transplant 
cardiac allograft setting where standard-of-care in many post-transplant clinics necessitates 
frequent highly invasive protocol biopsies to assess rejection at a histopathology level.
Genetics and genome-wide studies in heart transplantation
The human major histocompatibility complex (MHC) and natural killer cell 
immunoglobulin-like receptor (KIR) regions
The Human MHC region, located on the short arm of chromosome 6, comprising ~200 
coding genes including the HLA Class I (HLA-A,-B, and -C), II (HLA-DPA1,-DPB1,-
DQA1,-DQB1,-DRA, and -DRB1), and III gene families, with HLA Class I and II exons 
being the most polymorphic regions observed across the human genome. The MHC region 
consistently shows the strongest associations for a wide range of diseases and phenotypes 
[9], and associations of HLA polymorphisms with transplant outcomes are well-established 
[18–21]. HLA Class I/II molecules are key proteins responsible for the presentation of 
endogenously and exogenously derived peptides to T cells.
HLA Class I and Class II matching is well established in graft outcomes in renal and 
hematopoietic cell transplantation (HCT). While there is a clear role for HLA compatibility 
in transplantation outcomes of other solid organs, currently, the use of HLA matching is not 
performed in all heart transplant regions, because oflimited availability of organs and time 
constraints with HLA typing and recovery of organs. De novo antibody production has a 
clear impact on cardiac allograft recipient survival (Hazard Ratio > 3), with HLA Class II 
DQ-specific donor-specific antibody (DSA) being observed with poorer outcomes [22,23]. 
There is also an increasing body of evidence that nonclassical HLA molecules, such as 
HLA-G, also impact transplant outcomes [24,25,26]. There is a major need for more 
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comprehensive catalogs of polymorphisms across the HLA Class I, II, and wider MHC 
regions such as the Immuno Polymorphism Database (IPD) which contains a wealth of HLA 
alleles [27], although there is still a limited amount of HLA datasets from non-EA 
populations. There is an ever-growing body of clinical data showing that epitope-based HLA 
matching is superior to conventional HLA antigen matching for a range of post-transplant 
clinical outcomes, and it is likely that these approaches will become a major consideration in 
clinical D-R matching in the next few years [28,29].
The KIR region, the second most polymorphic region in the genome after the MHC, is 
comprised of a family of 13 genes on chromosome 19 [30]. KIRs play essential roles in 
educating and regulating the ability of NK cells to sense and respond to HLA Class I surface 
expression and have been shown to have critical roles in human health and are implicated in 
multiple immune-related diseases [31–33], and clinical studies show associations of 
combinatorial diversity of KIR and HLA alleles with multiple diseases, including infections 
and autoimmune disorders [18,20,21]. KIR/HLA Class I incompatibility exemplifies how 
interactions may negatively impact histocompatibility and while the impact of KIR-HLA 
mismatch in transplantation is controversial [21,34], recent studies do show evidence of KIR 
genotype associations with kidney and HCT transplant-related outcomes [35–37], although 
no well-powered studies to date have been performed in heart transplantation. There is some 
recent intriguing data that indicate that surveillance of CD28 and KIR2D receptor expression 
on T lymphocytes correlate with immune status of both heart and liver recipients [38]. As 
KIR and HLA Class I genes are located on different chromosomes, the statistical power to 
assess potential SNP–SNP interactions becomes very constrained. Where HLA and KIR 
have not been directly sequenced, it is possible to infer or “impute” HLA and KIR amino 
acid status from GWAS, WES, and WGS datasets using a number of different open-source 
algorithms [39–42]. Such approaches may add significant insight into additional HLA/KIR 
associations with transplant outcome particularly where samples were not typed at high 
resolution or at all, which is the case for most liver transplant centers.
Genetic association studies in transplantation across the rest of the human genome
It is also becoming increasingly evident that non-HLA variants, often termed minor 
histocompatibility antigen (mHA), impact rejection risk in transplantation [6,7,43,44]. In 
females receiving a male kidney allografts, worst survival outcomes were observed versus 
all other gender–gender D-R combinations [45]. This has been attributed in part to the H-Y 
antigen, against the Y-chromosome male-enhanced antigen MEA1 gene which has been 
associated with acute renal rejection [46]. D-R genetic differences in mHA across the entire 
human genome have yet to be investigated at large-scale in the solid organ transplant setting 
let alone in the cardiac transplant setting.
Association studies of polymorphisms in a priori candidate genes are notorious for 
publication bias and spurious and inconsistent results, and there are often confounding issues 
across sites such as adjustment for ancestry of the study participants [47]. The majority of 
genetic studies in transplantation outcomes published to date have mostly been limited to a 
priori candidate gene regions, suffer from small study sample sizes, and lack of replication 
in independent studies. The clinical and demographic covariates of recipient and donors in 
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transplantation are extremely complex relative to most common genetic disease studies, and 
it is thus not surprising that apart from pharmacogenetic/genomic studies with large effect 
sizes in genes known to impact that replication of initial findings is limited.
To date, only a handful of solid organ transplant GWA studies have been performed in 
modest numbers of patients and have focused mostly on renal transplantation (reviewed in 
an accompanying review article in this edition [48]) with very few significant findings. The 
only GWA study using heart transplant subjects was performed in relation to skin cancer 
outcomes [49]. There have been several dozen candidate genes studies in the heart transplant 
field, but only two studies used over 500 DNA samples. Four beta-adrenergic receptor 
(βAR) polymorphisms were screened by Khush et al in donor hearts to assess left 
ventricular (LV) dysfunction after brain death in 1 043 heart transplant donors from 2001 to 
2006 [50]. The β2AR-46 SNP was significantly associated with LV systolic dysfunction in 
multivariable regression analyses, with carriage of the less common variants significantly 
impacting LV ejection fraction. The β1AR1165 and β2AR46 SNPs were associated with 
increased inotropic dopamine requirement during procurement of the allograft (OR of 2.6 
for requiring >10 µg/kg/min of dopamine compared to those with the homozygous wild-type 
genotypes). Gallardo and colleagues examined the impact of common mitochondrial 
variants and contiguous stretches of variants or “haplotypes,” on end-stage heart failure in 
patients undergoing heart transplantation, in relation to CAV and graft survival, in 450 
recipients, 248 donors, and 206 healthy controls [51]. Carriage of mitochondrial haplogroup 
H was significantly higher in recipients versus controls [OR: 1.86 (95% CI: 1.27–2.74), P = 
0.014, and in recipients versus donors (OR: 1.47 [95% CI: 0.99–2.19), P = 0.032]) after 
adjustment for age and sex. In CAV patients versus non-CAV patients, the haplogroup Uk 
was observed to be significantly more frequent (OR: 4.1 [95% CI: 1.51–11.42], P = 0.042). 
Additionally, haplogroups in the heart donor were observed to have no impact on the 
morbidity or graft survival after heart transplantation.
There is an ever-growing catalog of specific variants that impact drug uptake, metabolism, 
clearance, efficacy, and severe adverse events [52,53]. Large consortia, such as the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) [54] and the Pharmacogenomics 
Research Network (PGRN) [53], are making significant advances in discovery and 
systematic documentation of a number of these key pharmacogenes and specific 
polymorphisms of major clinical value. Transplant patients are exposed to large number of 
pharmacotherapies over extensive periods of time including, immunosuppressants, inotropic, 
anti-hypertensive, and dyslipidemia agents as well as anti-fungal, anti-viral and antibiotic 
treatments, and chemotherapies. Table 1 outlines the most commonly prescribed drugs pre- 
and postcardiac transplant, and known genes and variants which impact patient responses to 
these drugs. Table 1 also outlines the current CPIC and PGRN guidelines along with the 
current FDA recommendation for patient monitoring/testing for these drugs. There has been 
much focus to date on the pharmacogenetics/pharmacogenomics of tacrolimus, the most 
commonly used immunosuppressant, as there is high interindividual variability in dosing 
required to reach, and to maintain, optimal therapeutic trough levels [55]. The narrow 
therapeutic range requires close monitoring of plasma drug concentrations especially during 
the initial period post-transplant. Trying to balance avoidance of overimmunosuppression, 
which can lead to nephrotoxicity and increased risks of opportunistic infections, against 
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undersuppression of the allograft recipient, which can lead to increased risk of acute 
rejection, can be challenging in many patients [56]. While gender, age, BMI, type 2 diabetes 
status and exposure to calcium channel blockers influence tacrolimus blood levels and 
clearance, an intronic LoF variant CYP3A5*3 (rs776746), in cytochrome P450 3A5 
(CYP3A5), the main enzyme that metabolized tacrolimus, explains ~45% of drug level and 
30% of clearance. CYP3A5*1 classically referred to a functional gene copy of CYP3A5, but 
without ascertainment of all variants in the gene-coding regions, as well as in the intronic 
and untranslated regions, then a “CYP3A5*1 functional gene status” cannot truly be derived. 
Additional variants, including CYP3A5 *2, *5, *6, *7, *10, and CYP3A4 22*, cause LoF or 
reduced expression of these key enzymes and have been found to explain an additional 20% 
of the genetic variance in tacrolimus blood levels. The allele frequency of CYP3A5*3 is 
~82–95% in European ancestral populations and ranges from 33% in African to 75–85% in 
Asian and 75% in Mexican populations [57]. Higher carriage of LoF SNPs in CYP3A5, as 
observed in European, Hispanic, and Asian populations, invariably requires that less 
tacrolimus dosing be administered to reach and maintain optimal trough level, and indeed, 
less nephrotoxicity and side effects are observed because of lower cumulative tacrolimus 
exposure. African Americans are known to have higher rates of rejection following kidney 
transplantation, which may be caused in part from failure to reach therapeutic 
immunosuppression dosing of tacrolimus [58,59].
Ancestry has also been shown to play an important role in heart transplantation. A 
retrospective analysis of over 20 000 adult heart allograft recipients transplanted from 1997 
through 2007 assessed the impact of D-R race-matching, on mortality using 23 variables and 
D-R interaction terms. African Americans recipients were shown to have an 11.4% absolute 
decrease in 10-year survival and a 46% proportional increase in the risk of cumulative 
mortality (HR, 1.46; 95% CI, 1.24 to 1.72; P < 0.001) versus European recipients [60]. 
Decreased survival in recipients from African American allograft donors or any other racial 
groups was not observed to be improved with race-matched transplantation in this study. 
African Americans have been shown to exhibit poorer transplant outcomes versus those of 
European ancestry, even after adjusting for clinical and socioeconomic covariates [61]. 
Using United Network for Organ Sharing (UNOS) registry data for 14 265 heart transplant 
patients, a 13-point risk score incorporating age, race, sex, HLA matching showed high 
predictive ability for clinically important rejection episodes within 1 year [62]. Race was 
observed to impact one-year rejection rates; when excluding individuals of European 
ancestry, individuals of non-European ancestry had comparable rejection rates, with the 
exception of cardiac allograft recipients of Asian descent, who had reduced rates of 
rejection.
The international genetics & translational research in transplantation network 
(iGeneTRAiN)
Large well-characterized numbers of genome-wide datasets are needed for D-R pairs or for 
recipient-only samples, to accrue sufficient numbers of transplant-related phenotypes/events 
[63]. This was one of the main considerations for establishing iGeneTRAiN, whose initial 
aims are to generate and harmonize genome-wide genotyping and phenotypic datasets across 
transethnic heart, kidney, liver, and lung transplant studies, and integrating analyses and risk 
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models to increased statistical power to detect transplant-related outcomes ([63] and 
www.igenetrain.org).
iGeneTRAiN has now aggregated GWAS and phenotypic datasets from >48 000 DNAs from 
transplant subjects and controls (with >12 000 D-R pairs), collected from 1989 to present, 
including >1 800 heart transplant recipients and >1 000 of their respective deceased donors 
[49,63–67]. A dedicated GWAS array, the “TxArray,” with 780 000 markers, designed for 
the transplant community by iGeneTRAiN, provides robust genome-wide coverage using 
conventional genome-wide mapping content, but with dense coverage of variants in key 
transplant-related regions, such as MHC, KIR and is enriched for recent pharmacogenomic 
and CKD related-findings [27]. Furthermore, a deep collation of all published cardiac 
allograft genetic association studies (and all other solid organs) up to 2015 was performed, 
and probes for these genetic variants were directly captured on the array to allow for meta-
analyses with previous publications. A dedicated pipeline for quality control and processing 
of the GWAS data has been developed (see Fig. 1) for the transplant community. A number 
of clinically relevant transplant outcomes, including graft and patient survival, acute and 
chronic rejection, new-onset of diabetes after transplant (NODAT), cause of transplant, and 
various malignancies, are being investigated using recipient-only, donor-only, and various D-
R models.
Diagnostics & prognostication biomarker studies of post-transplant 
complications
Most transplant centers currently diagnose cardiac allograft rejection through histological 
evaluation of endomyocardial biopsy (EMB) from surveillance standard-of-care visits or 
from “for-cause” biopsies after the onset of clinically observed allograft dysfunction. EMBs 
are costly, highly invasive and are subject to interobserver variability and sampling errors at 
the histopathology level [68]. Furthermore, surveillance biopsies may detect allograft 
rejection after irreversible damage has already occurred. Early identification of biological 
markers of subclinical allograft rejection and/or injury using highly sensitive and specific 
assays may allow more timely intervention to preserve graft function and thus increase 
allograft lifespan. The development of diagnostic and prognostic biomarkers of allograft 
dysfunction has been a major endeavor of many groups over the last two decades, with most 
of the focus being on the transcriptome (mRNA and miRNA studies) and donor-derived cell-
free DNA (dd-cfDNA) [69].
Messenger RNA (mRNA) studies
The Cardiac Allograft Rejection Gene Expression Observational (CARGO) study, which 
began in 2001 [70], collected blood and EMBs from the corresponding timepoints of heart 
allograft recipients across eight sites and identified altered expression of 11 genes which 
discriminates acute cellular rejection (ACR) from immunologically quiescence timepoints. 
The CARGO investigators also developed an expression-based algorithm with a score from 
0 to 40, where higher scores (34 or higher) are indicative of an acute rejection episode. This 
assay was developed into an FDA approved in vitro diagnostic (IVD) and is available for 
clinical use in stable heart allograft recipients. A number of additional studies including the 
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Invasive Monitoring Attenuation through Gene Expression (IMAGE) Study compared 
AlloMap to protocol EMB as the primary means of ACR surveillance assessing primary 
outcomes of first rejection episodes with hemodynamic compromise allograft dysfunction, 
retransplantation, or death [71]. The IMAGE study observed similar outcomes in the 
AlloMap-alone versus EMB groups for primary outcome incidences (14.5% vs. 15.3%). The 
CARGO II study found that the negative predictive value (NPV) for a graft failure, 
retransplantation, or death was 97% where patients had an AlloMap score variability (AMV) 
of 0.6 (defined as the standard deviation of four Allo-Map scores collected at least 315 days 
post-transplantation with a 95% CI of 91.4–100) [72]. As of the middle of 2017, over 100 
000 blood samples from heart transplant recipients had been subjected to AlloMap assays.
A recent cardiac allograft rejection mRNA diagnostic study examined EMBs from four 
French transplant centers for antibody-mediated rejection (AbMR) (n = 55) with a control 
group of 55 biopsies without AbMR, and a Canadian validation cohort of 27 AbMR cases 
and 71 non-AbMR controls using ISHLT 2013 histopathology grading [73]. Genome-wide 
expression microarrays were used to molecularly characterize the entire 240 biopsies and 
demonstrated molecular pathways within the AbMR samples characterized by endothelial 
activation with microcirculatory inflammation from monocytes–macrophages and NK cells. 
They also showed changes in endothelial, angiogenesis, and NK cell mRNA expression 
profiles, including CD16A signaling and mRNAs, influenced by interferon-γ. Panels of 
AbMR-related transcripts demonstrated decent discrimination for AbMR biopsies versus 
non-AbMR: NK-related (AUC = 0.87), endothelial activation-related (AUC = 0.80), 
macrophage-related (AUC = 0.86), and interferon-γ-related (AUC = 0.84) (with P < 0.0001 
for all four sets). These four gene panels showed increased expression with increasing 
ISHLT grading of AbMR pathology (P < 0.001) and association with DSA levels. These 
samples are part of a major international effort called Molecular Microscope Diagnostic 
System (MMDx) examining AbMR and T-cell mediated rejection (TCMR) and other post-
transplant compilations across a range of solid organ allograft biopsies. These are, and will 
undoubtedly continue to be, a significant reference resource for characterization of subtypes 
of rejection as well as other complications of rejection such as CAV. Indeed, subsets of the 
expression classifiers of AbMR in the study showed association with CAV [73]. Array-based 
expression platforms have a number of limitations compared to more recent methods which 
include sequencing RNA transcripts (RNA-Seq). When comparing human T-cell activation 
using RNA-Seq against microarray-based-expression, RNA-Seq demonstrates superiority in 
dynamic range, as well as for detection of low abundance transcripts, and differentially 
expressed mRNA isoforms [74].
MicroRNA (miRNA) studies
Noncoding RNAs include microRNAs (miRNAs), which are typically 22 nucleotides in 
length, are potent regulators of transcriptional and post-transcriptional gene expression. 
They have been shown to disperse into the periphery circulatory system from cells within 
solid organs, and their small sizes make them less susceptible to RNase enzymatic 
degradation. Furthermore, they are generally stable in blood at room temperature for up to 
48 hours, and thus, they are an attractive target to assess patterns of injury or recovery in 
disease processes [75]. In one of the most recent and largest cardiac allograft miRNA study 
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conducted to date, EMBs from 113 heart transplant recipients from four French transplant 
sites (discovery component n = 60, validation cohort, n = 53) [76] were screened for miRNA 
levels. In the discovery arm, miRNA expression was compared between EMBs and sera 
from patients with acute biopsy-proven allograft rejection (n = 30) versus controls subjects 
without rejection (n = 30). Seven miRNAs were observed to be differentially expressed 
between allograft rejection timepoints versus nonrejection biopsies (P < 0.0001). Of these 
seven miRNAs, four were observed to be detectable and exhibited differential expression in 
sera. The ROC analyses showed that these four circulating miRNAs strongly discriminated 
allograft rejection versus those without rejection (all had AUC ranging from >0.93 to >0.99 
with P < 0.0001), and these signals were confirmed with an additional replication set of 
cardiac allograft patient sample sets. Furthermore, the discrimination capability of the four 
miRNAs remained significant when stratified by TCMR versus AbMR diagnoses, and time 
post-transplant.
Cell-free circulating DNA (cfDNA) studies
Stemming from seminal noninvasive prenatal diagnoses (NIPDs) research which assesses 
fetal DNA in maternal blood, the cfDNA approaches in transplantation take advantage of 
donor-derived circulating cfDNA (dd-cfDNA) which has been shown to increase in ratio 
when compared with recipient DNA after necrosis/apoptosis of donor allograft cells/tissue 
[77]. Panels of several hundred SNPs across the genome, whose frequencies are high in the 
most common human populations, can be used to discriminate donor and recipient DNA 
ratios in the blood of kidney, lung, and heart recipients. The dd-cfDNA method was first 
successfully applied in heart transplantation in a retrospective study where increased levels 
of dd-cfDNA were shown to correlate with ACR episodes using EMB as the reference 
pathological standard [78]. The clinical utility of dd-cfDNA in monitoring acute rejection 
was subsequently tested in a prospective heart transplant recipient study [79]. dd-cfDNA 
was shown to be highly elevated from day 1 post-transplant (indicative of early ischemia–
reperfusion injury postsurgery), followed by a quick decline to <0.1% within a week, and 
remained low until a rejection event. The performance of dd-cfDNA in distinguishing 
ISHLT Grade 2 or 3 rejections from immunological quiescence had an observed AUC of 
0.83, with a sensitivity of 58% and a specificity of 93%. The authors also outlined the use of 
dd-cfDNA monitoring as a prognostic monitoring assay for rejection as levels of dd-cfDNA 
were observed to be significantly elevated weeks to months preceding a rejection episode. 
As dd-cfDNA can be assessed at defined periods post-transplant, in a minimally invasive 
manner, and as it is essentially a quantitative read-out of donor versus recipient cfDNA, then 
it can also be used in a prognostic manner to monitor heart allograft status. Cell-specific dd-
cfDNA approaches, using methylation and/or histone mapping, to identify the cell(s) or 
tissue of origin of the cfDNA, are now emerging as powerful tools to delineate the 
underlying cause of increased dd-cfDNA [80,81].
Discussion and future directions
To date, genetic association studies in heart transplant studies have mostly been limited to 
the HLA and pharmacogenomic setting, although a number of large-scale GWA studies 
including iGeneTRAiN are now underway with GWAS from >1 800 heart allograft 
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recipients and >1 000 donors. There are still significant challenges that have to be overcome 
though and greater numbers of samples are needed, as well as collaboration between sites 
for more comprehensive phenotype harmonization, as adjusting for clinical and 
demographic recipient and donor covariates across sites can be very challenging. A wealth 
of existing DNA already exists for donor and recipient DNA samples from organ 
procurement organizations (OPOs) and HLA reference laboratories. With appropriate 
regulatory approval, these D-R genomic and outcome datasets can be linked with medical 
records (EMRs) and national-level databases such as the Scientific Registry of Transplant 
Recipients (SRTR), the most powerful registry in the United States, for assessment of long-
term post-transplant outcomes [82]. Knowledge gained from how MHC, KIR, and mHA 
variants impact outcomes will facilitate greater insight into the potential biology of genomic 
incompatibility of D-R pairings, which may lead to better patient care through more regular 
monitoring of recipients paired with a higher genetic-risk donor. With the increased use of 
LVADs and rapid-HLA genotyping, more appropriate D-R matching prior to transplantation 
may be possible based on MHC/HLA, KIR, and mHA genotype combinations.
In the last decade, there have been significant advances in the development of molecular 
tools for the diagnoses and prognoses of acute and chronic rejection, as well as other 
complications post-transplant. While there are better international classifications of acute 
rejection, there are still significant issues with histopathology grading, and there is an 
increasingly clear case for molecular characterization of the EMB for diagnoses and 
prognostication of various outcomes. Furthermore, blood samples from the same timepoints 
will likely have value for immune surveillance in a minimally invasive manner as we move 
toward miRNA, mRNA, and dd-cfDNA laboratory developed tests (LDT) and IVD assays 
with better sensitivity and specificity [71,83–85]. Ultimately, with robust enough 
biomarkers, such approaches could lead to personalization of immunosuppression therapy to 
limit side effect, but great caution is needed in this area [86].
Comparing biomarker signatures across different solid organ allograft studies is also an area 
of major value as while there are clearly organ-specific signals in post-transplant outcomes, 
there is also biological overlap in a number of processes related to rejection and other post-
transplant complications across all solid organ transplants. Levels of miR-21 were observed 
to be associated with AR, fibrosis, and CAV in heart recipients [76,87] but were also 
associated with ischemia–reperfusion injury, fibrosis AbMR, and other complications in 
kidney [88–91] and with graft dysfunction in lung allografts [92]. Furthermore, downstream 
miRNAs derived from miR-142 (miR-142-5p and miR-142-3p) are associated with AR, 
chronic rejection, and/or fibrosis across all four major solid organ transplantations [92–96]. 
Levels of miR-223p-3p and miR-93-5p were shown to be present in CKD stages [97], which 
may also have broad utility for routine monitoring of kidney function in cardiac and other 
allograft patients especially when combined with miRNAs that are known to have clinical 
utility in post-transplant surveillance. Furthermore, assessment of 10 genes expressed in 
blood that are diagnostic of kidney acute rejection was shown to have utility in a study of 
250 blood samples from heart transplant recipients with and without acute rejection, 
indicating common pathways of immune activation [65].
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Genomic and other omic applications will undoubtedly start to play a more significant role 
in the personalization of patient management in the heart transplant setting. Ascertaining the 
genetic underpinnings of various types of cardiac allograft rejection and complications post-
transplantation will yield significant advances in our understanding of fundamental 
molecular processes involved in such processes. Identification of potential new genomic 
biomarkers for diagnoses and prognostication of post-transplant outcomes, as well as risk 
stratification of transplant patients, is also likely to result from such studies.
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Figure 1. 
iGeneTRAiN Genome-wide association study analyses (GWAS) pipelines. The genome-
wide association study analyses (GWAS) for The International Genetics & Translational 
Research in Transplantation Network (iGeneTRAiN) is illustrated from assessment of the 
DNA quality for the different studies, through to the wet-laboratory processing of the 
genome-wide genotyping plates to generate several hundreds of thousands of SNP/SNV 
genotype calls. The pipelines for genome-wide imputation (IMPUTE2 and ShapeIT) HLA 
(SNP2HLA, HLA*IMP) and KIR (KIR*IMP) are generated and phased. The loss-of-
function (LoF) pipeline using VEP and LOFTEE utilizes the phased imputed GWAS data 
(typically 15 million variants) and copy number variant (CNV) is generated from the raw 
image files using standard Affymetrix pipelines or PennCNV [98]. The donor–recipient 
interaction analyses utilized the imputed LoF and CNV datasets, using ancestry data derived 
from the GWAS data and other means including genome-wide amino acid mismatches. 
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Finally, the phenotypes and covariates of interest are integrated with the various GWAS-
derived datasets primarily using PLINK [99].
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